Glanz: Aging daily 72fa95503e0e41389f487fadfdf2ad46 32a26ca0a21b

2026-09-30T06:22:37Z

Aging daily 72fa95503e0e41389f487fadfdf2ad46 32a26ca0a21b

Neue Seite

__NOTOC__
<div class="aging-research-world aging-journal" lang="en">
<div class="aj-masthead"><div class="aj-brand"><span class="aj-monogram">[[Aging|a.]]</span><span>[[Aging|AGING]]<small>RESEARCH IN PROGRESS</small></span></div><div class="aging-languages" role="navigation" aria-label="Sprache / Language"><span class="aging-language" title="Deutsch">[[Altern/Forschungsberichte/2026-09-30|🇩🇪]]</span><span class="aging-language" title="English">[[Aging/Research reports/2026-09-30|🇬🇧]]</span></div></div>
<div class="aj-context"><strong>An evolving AI research project</strong>[[Aging/About the project|Background · goals · methods]]<span>Updated 30 Sep 2026</span></div>
<h1>Where does the tau go?</h1>
<div class="aj-deck">Research report · 30 September 2026 · Tau, measurement and degradation</div>
<div class="aj-article">

<div class="aging-note">'''Where does the tau go?'''

Today's source audit strengthens lysosomal processing as an explanation but does not establish a quantitative balance of complete degradation. '''🔵 AG-C03 / AG-T01 remains Level 2, low confidence.'''</div>

== The decision ==
Yesterday identified export as a competing explanation. Today examines the measurements: '''We provisionally reject calculating the degraded fraction from the available signal losses.''' This rejects neither lysosomal processing nor TIMP2 as a candidate. It limits what these data can establish for our goal of lasting improvement in neuronal function.

One primary study joins the register: '''AG-D02''', Shultz et al., online '''18 August 2025''', issue date 15 October 2025, DOI 10.1016/j.nbd.2025.107058. AG-D01, published 6 April 2026, receives a targeted follow-up on Figure 4 and measurement methods for a new, explicit question. The register now contains '''24 DOI-unique studies'''. “New” means newly included, not published today.

== Two measurement routes, different conclusions ==
'''AG-D02 · Tau-HiBiT:''' A luminescent reporter tracks tau after uptake and washout. RAB7A knockdown and lysosomal damage in H4 cells slow signal loss, supporting lysosomal involvement. This validation must be distinguished from the iPSC-microglia comparisons. Signals are normalized to their respective starting values. This does not yet quantify degradation through a jointly calibrated balance of cells, medium and fragments. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12790857/ Primary manuscript] · [https://pubmed.ncbi.nlm.nih.gov/40835173/ Publication metadata and figure legends]

'''AG-D01 · Cell signal plus medium:''' Figure 4 combines Tau12 immunofluorescence with a total-tau ELISA in medium. These do not directly form a common mass balance; the ELISA epitopes are proprietary. A timing discrepancy also remains: the text mentions six hours of clearance, whereas the figure shows a 24-hour chase; its 6/24-hour groups denote loading durations. We do not silently combine these as a time series. [https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71337 Primary study, methods 2.8/2.14 and Figure 4]

== Evidence and project significance are separate ==
* '''Established methodological knowledge · ⚪ Level 1:''' Relative signals, concentrations and total amounts are different quantities. A joint balance needs compatible calibration, volume, cell accounting and definitions of detected molecules.
* '''Promising indication · ⚪ Level 1:''' AG-D02's perturbations support lysosomal involvement in the cell model. Moderate evidence for this limited mechanism, not rejuvenation.
* '''External experimental results · ⚪ Level 1:''' The papers examine different tau species, cell models and assays. They provide complementary observations, not a joint test of the TIMP2 pathway.
* '''Project synthesis · 🔵 Level 2:''' AG-T01 still requires selective cargo degradation, preserved useful synapses, meaningful functional benefit and no harmful redistribution. The complete chain is unconfirmed; novelty remains unverified.

== Why we are not calculating a degradation rate today ==
A normalized signal can be represented as:
<pre>r(t) = [S(t) − B] / [S(0) − B]</pre>
S denotes the measurement response and B the appropriate background. r is dimensionless; its denominator must be nonzero. '''1 − r(t) initially denotes relative signal loss''', not necessarily the fraction of completely destroyed tau molecules. Initial loading, reporter/epitope loss, export, cell loss and reuptake must be accounted for in the relevant measurement model. This distinction is our methodological inference, not a new measurement.

We have not verified a sufficiently matched dataset to separate these contributions quantitatively. A precise-looking fitted curve would not supply the missing information. Therefore, no effect estimate, half-life or cross-study pooling is calculated today. Instead, the audit makes a concrete decision about which analysis the current evidence permits.

== Countermodels and the next executable step ==
The next source check will examine which tau fragments and antibody epitopes survive processing: '''AG-D01, sections 3.5–3.6 and method 2.13.4, plus accessible related supplements (peptide mapping: S9C/D)'''. The output should map detected fragment, assay response, possible blind spot and relation to seeding activity. The timing discrepancy stays unresolved until a checkable source resolves it. Missing supplementary data will not be guessed.

Later external confirmation would need to assess cargo fate together with preserved synapses, neuronal function, durability and harms. Our next step is source analysis; this project performs no laboratory or clinical studies. No new efficacy claim is made for the axolotl branch today. Injury regeneration and aging reversal remain distinct questions.

== Provenance, limitations and research log ==
AG-D02 is the peer-reviewed version of an earlier preprint; both count as one study, not replication. AG-D01 cites AG-D02. Different methods alone do not establish fully independent confirmation. A joint test of AG-T01 is absent.

Retrieved '''30 September 2026'''. Targeted searches covered microglia/tau/degradation/export and measurement methods; AG-D02 DOI/title searches for correction/retraction found no matching notice, not a comprehensive registry audit. AG-D02: direct publisher/PMC retrieval blocked; indexed primary methods and figure legends assessed. AG-D01: publisher full text and Figure 4 assessed; supplementary access limited. No comprehensive September search or raw-data reanalysis.

This methodological deepening adds reading for AG-P17–20. No duplicate professor package or reset wish-list entry; existing assignments are preserved. No personal treatment plans or self-medication advice.

</div>
<div class="aj-section-title"><h2>Continue exploring</h2></div><div class="aj-tiles"><div class="aj-tile"><div class="aj-thumb">[[File:Bovine Pulmonary Artery Endothelial Cells Fluorescent Image.jpg|120px|frameless|link=Aging/Approaches to aging|alt=Fluorescence micrograph of bovine endothelial cells with labeled nuclei, actin and mitochondria.]]</div><div><div class="aj-tile-title">[[Aging/Approaches to aging|Approaches to aging]]</div><div class="aj-tile-desc">Evidence and functional outcomes</div></div></div><div class="aj-tile"><div class="aj-thumb aj-type-thumb">[[Aging/Evidence chain|→]]</div><div><div class="aj-tile-title">[[Aging/Evidence chain|Evidence chain]]</div><div class="aj-tile-desc">How studies generate new questions</div></div></div><div class="aj-tile"><div class="aj-thumb">[[File:DNA double helix.svg|120px|frameless|link=Aging/Research colloquium|alt=Schematic illustration of a DNA double helix.]]</div><div><div class="aj-tile-title">[[Aging/Research colloquium|Research colloquium]]</div><div class="aj-tile-desc">16 foundation assignments + 4 new deep dives</div></div></div></div>
<div class="aj-footer"><div class="aj-brand"><span class="aj-monogram">[[Aging|a.]]</span><span>[[Aging|AGING]]<small>RESEARCH IN PROGRESS</small></span></div><div class="aj-context">[[Aging|Project overview]][[Aging/About the project|Goals & methods]][[Aging/Evidence chain|Evidence chain]]</div><div class="aj-meta">AI-assisted literature research and model building. No laboratory or clinical studies conducted by this project. No personal treatment plans.</div><div class="aj-credits">Image credits · Illustrations, not project data: [https://commons.wikimedia.org/wiki/File:Axolotl_Portrait.jpg Axolotl] — LoKiLeCh ([https://creativecommons.org/licenses/by-sa/3.0/ CC BY-SA 3.0]) · [https://commons.wikimedia.org/wiki/File:XBio_illustration_%E2%80%93_Neuron.png Neuron] — explorebiology (Explore Biology) ([https://creativecommons.org/licenses/by/4.0/ CC BY 4.0]) · [https://commons.wikimedia.org/wiki/File:DNA_double_helix.svg DNA] — Biochemlife ([https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0]) · [https://commons.wikimedia.org/wiki/File:Bovine_Pulmonary_Artery_Endothelial_Cells_Fluorescent_Image.jpg Bovine endothelial cells] — Erin Rod ([https://creativecommons.org/licenses/by/4.0/ CC BY 4.0])</div></div>
</div>
[[Category:Altern / Aging]]

Aging/Research reports/2026-09-30 - Versionsgeschichte

Glanz: Aging daily 72fa95503e0e41389f487fadfdf2ad46 32a26ca0a21b